Eam Global Investors LLC Affimed N.V. Transaction History

Eam Global Investors LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 12, 2021	SELL	$5.54 - $7.51 $1.18 Million - $1.6 Million	-212,481 Closed	0 $0
Q2 2021 Aug 13, 2021	SELL	$7.78 - $11.4 $998,352 - $1.46 Million	-128,323 Reduced 37.65%	212,481 $1.81 Million
Q1 2021 May 11, 2021	SELL	$5.12 - $8.48 $102,231 - $169,320	-19,967 Reduced 5.53%	340,804 $2.7 Million
Q4 2020 Feb 11, 2021	BUY	$3.16 - $7.03 $1.14 Million - $2.54 Million	360,771 New	360,771 $2.1 Million
Q2 2019 Aug 14, 2019	SELL	$2.6 - $4.21 $837,824 - $1.36 Million	-322,240 Closed	0 $0
Q4 2018 Feb 13, 2019	SELL	$2.82 - $4.67 $429,336 - $710,993	-152,247 Reduced 32.09%	322,240 $1 Million
Q3 2018 Nov 08, 2018	BUY	$1.45 - $6.15 $688,006 - $2.92 Million	474,487 New	474,487 $2.06 Million

1.09M

Ticker AFMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 149,339,008
Market Cap $185M
Description
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in P...

Get notified when there are updates to the investment portfolio of Eam Global Investors LLC, based on Form 13F filings with the SEC.

Stay updated on Eam Global Investors LLC with notifications on news.